Hookipa Pharma (NASDAQ:HOOK) PT Lowered to $23.00

Hookipa Pharma (NASDAQ:HOOK) had its price objective cut by investment analysts at JMP Securities from $50.00 to $23.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. JMP Securities’ target price would indicate a potential upside of 270.37% from the company’s previous close.

A number of other analysts have also commented on the company. Royal Bank of Canada restated an “outperform” rating and issued a $50.00 price target on shares of Hookipa Pharma in a report on Tuesday, May 21st. HC Wainwright boosted their target price on Hookipa Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, June 5th.

Hookipa Pharma Trading Down 1.7 %

Shares of NASDAQ:HOOK traded down $0.11 during trading on Friday, hitting $6.21. 7,969 shares of the company’s stock traded hands, compared to its average volume of 69,573. The company has a 50-day moving average price of $7.05 and a 200-day moving average price of $7.31. Hookipa Pharma has a 52 week low of $4.10 and a 52 week high of $11.30. The company has a market cap of $61.48 million, a price-to-earnings ratio of -1.24 and a beta of 0.81.

Hookipa Pharma (NASDAQ:HOOK) last announced its quarterly earnings results on Thursday, May 9th. The company reported $1.20 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.20) by $2.40. Hookipa Pharma had a negative net margin of 88.73% and a negative return on equity of 33.33%. The firm had revenue of $36.60 million for the quarter, compared to analyst estimates of $3.20 million. During the same quarter in the previous year, the firm posted ($2.70) earnings per share. On average, analysts predict that Hookipa Pharma will post -3.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Hookipa Pharma stock. Virtu Financial LLC purchased a new position in shares of Hookipa Pharma Inc (NASDAQ:HOOK) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 43,021 shares of the company’s stock, valued at approximately $31,000. Hedge funds and other institutional investors own 63.88% of the company’s stock.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.